Ursula A. Matulonis, MD
Medical Director, Gynecologic Oncology
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston,
MA
USA
MA02215
Biographical Sketch: Dr. Ursula A. Matulonis is Medical Director and Program Leader of the Medical Gynecologic Oncology Program at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. Her research focuses on targeted therapies for gynecologic malignancies, with a specific interest in the genetic changes in ovarian cancer and how that can lead to rationale targeted drug selection. Dr. Matulonis is the Principal Investigator of several clinical trials and translational studies for ovarian cancer. Dr. Matulonis is a Co-PI on the project “Genetic relationships between breast and ovarian cancer” that is funded by the Breast Cancer Research Foundation and was recently awarded a 2012 Department of Defense Ovarian Cancer Research Program Award that will study the prediction of response to therapy and clinical outcome through complete genetic assessment of different histologic subtypes of ovarian cancer. Dr. Matulonis serves on the National Comprehensive Cancer Network Recommendation and Guideline Committee for both ovarian cancer and for the treatment of anemia, the Gynecologic Oncology Group Quality of Life and Ovarian Committee, a member of The Cancer Genome Atlas Project (TCGA) Endometrial Analysis Working Group, and is Medical Director and Board Member for the non-profit organization Ovations for the Cure. She is a recipient of the Dennis Thompson Compassionate Care Scholar award, the Lee Nadler “Extra Mile” award, the Lenny Zakim patient advocate award and the Susan M. Love award and was named one of Boston’s Best Physicians in Medical Oncology by Boston Magazine numerous times. After receiving her undergraduate degree from Rensselaer Polytechnic Institute In Biology and an MD degree from Albany Medical College, she completed an internship and residency at the University of Pittsburgh, followed by a medical oncology fellowship at Dana-Farber."
Papers:
132 - Focused Plenary
Analysis of intermediate clinical endpoints from a Phase II trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)